主要胆管胆管炎患者的二线治疗:通过网络元分析进行系统性审查
Edoardo G Giannini1,2,3, Andrea Pasta1,2, Francesco Calabrese1,2
1Gastroenterology Unit, Department of Internal Medicine, University of Genoa, Genoa, Italy.
概括
对于对ursodeoxycholic acid反应不完全的初级胆汁胆炎 (PBC) 患者,elafibranor与seladelpar相比显示出更好的生化反应. 塞拉德尔帕减少了,而肥酸增加了和严重的不良事件.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 初级胆道胆炎 (PBC) 影响许多患者,这些患者对ursodeoxycholic acid (UDCA) 没有充分的反应.
- 第二线治疗对于预防不响应患者的疾病进展至关重要.
- 以前无法直接比较这些二线治疗方法.
研究的目的:
- 使用网络元分析 (NMA) 来比较PBC可用的二线疗法的疗效和安全性.
- 确定对UDCA反应不足或不耐受性患者的最佳治疗策略.
主要方法:
- 进行了随机,安慰剂对照试验的系统文献审查.
- 网络元分析 (NMA) 用于比较生化反应,和严重不良事件 (SAE) 的相对风险 (RR).
- 包括的试验集中在患有PBC的患者和对UDCA的不充分反应或不耐受.
主要成果:
- 与seladelpar.com相比,Elafibranor在实现生化反应方面表现出更高的疗效.
- 塞拉德尔帕是唯一一种与减少新发的发病率相关的治疗方法.
- 与安慰剂相比,肥酸 (OCA) 与和SAE风险增加有关.
结论:
- 埃拉非布拉诺在生物化学反应方面比seladelpar提供了轻微的优势.
- 塞拉德尔帕在降低发病率方面具有独特的益处.
- OCA的疗效与其他药物相当,但和SAE的风险概况较高,这表明PBC的个性化治疗方法.
相关概念视频
01:29Chronic Pancreatitis II: Collaborative Care
46
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
46
01:17Chronic Bowel Disorders: Introduction
298
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
298
01:29Inflammatory Bowel Disease IV: Pharmacological Management
79
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
79
01:30Acute Pancreatitis II: Clinical Manifestations and Management
65
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
65
01:26Peptic Ulcer Disease IV: Management
45
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
45